Oct 23rd 2012 - Edison Investment Research today published a report on wilex entitled "Völlig Baff (gobsmacked) Survival". In summary, the report says:
Redectane and Mesupron are now Wilex’s key products after the Rencarex Phase III ARISER data showed no efficacy; Rencarex has been discontinued. After the July ODAC meeting determined that a hypothetical imaging test for clear cell renal carcinoma would be clinically useful, the FDA agreed that a Redectane confirmatory study could lead to a US filing. The design and timing of the REDECT-2 Phase III are being finalised. Mesupron has good Phase II data in both pancreatic and HER-2 negative breast cancer and could be partnered in 2013. Wilex is funded into 2014; Q3 cash was €28.7m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »